Document:

<PAGE>

                                 PROMISSORY NOTE

Amount of $278,026.60                                   As of December 21, 2000
           ----------

     FOR VALUE RECEIVED, Long Distance Direct Holdings, Inc. ("Maker"), a Nevada
corporation, does hereby promise to pay to the order of PowerChannel Holdings,
Inc. ("Holder"), a Delaware corporation having an address at 20 Squadron Blvd.,
Suite 210, New City, NY 10956, the principal sum of Two Hundred Seventy-Eight
Thousand Twenty-Six 60/100 Dollars and Sixty Cents ($278,026.60), with simple
interest thereon at the rate of seven and one-half percent (7.5%) per annum,
until maturity. The principal and all accrued interest due under this Note shall
be paid in full on or before June 30, 2001 (the "Maturity Date").

     This note memorializes an oral understanding between the parties. Pursuant
to such oral understanding, Holder has advanced funds to Maker at various times
and in various amounts, all as set forth on the Schedule appearing on the
signature page hereof. Interest shall accrue only on the amount of principal
actually outstanding from time to time.

     The indebtedness evidenced by this Note may be prepaid in whole or in part
at any time without penalty or premium. Any and all such prepayments shall be
paid with interest on the amount being prepaid through the date of such
prepayment.

     If Maker fails to repay this Note in full, along with accrued interest, on
or prior to the Maturity Date, Maker undertakes that it shall deliver to Holder
the number of the shares of Holder's common stock owned by Maker, with each
share being valued at $1.00 per share, equivalent to the principal amount, plus
accrued interest, not repaid. Maker consents to the entry in the Holder's share
registry of a stop-transfer notation on 300,000 shares of Holder's common stock
owned by Maker and to the cancellation of such shares in the event this Note is
not paid as agreed.

<PAGE>

     The outstanding principal amount of this Note shall be accelerated and
shall become immediately due and payable upon the occurrence of any of the
following events:

     (i)  Maker shall file a petition or otherwise seek relief from creditors in
          any proceeding under any bankruptcy, reorganization, moratorium or
          similar laws for the relief or benefits of creditors (such laws,
          collectively, "Bankruptcy Laws");

     (ii) a petition shall be filed against Maker in any proceeding under any
          Bankruptcy Laws and either (a) Maker shall consent thereto or
          acquiesce therein or (b) the same shall not be discharged or reversed
          within thirty (30) days;

    (iii) a receiver, liquidator, sequestrator or similar official shall be
          appointed by any court of competent jurisdiction over Maker or any
          substantial portion of its business and assets;

     (iv) Maker shall admit in writing its inability, or shall become unable, to
          pay its debts generally as they become due.

     Presentment for payment, demand, protest and notice of demand, notice of
dishonor and notice of nonpayment and all other notices are hereby waived by
Maker. No failure to accelerate the debt evidenced hereby by reason of default
hereunder, acceptance of a past due installment, or indulgences granted from
time to time shall be construed (1) as a novation of this Note or as a
restatement of the indebtedness evidenced hereby or as a waiver of such right of
acceleration or of the right of the Holder thereafter to insist upon strict
compliance with the terms of this Note, or (2) to prevent the exercise of such
right of acceleration or any other right granted hereunder or by applicable law;
and Maker hereby expressly waives the benefit of any statute or rule of law or
equity now provided, or which may hereafter be provided, which would produce a
result contrary to or in conflict with the foregoing. No extension of the time
for the payment of this Note or any installment due hereunder, made by agreement
with any person now or hereafter liable for the payment of this Note shall
operate to release, discharge, modify, change or affect the original liability
of the Maker under this Note, either in whole or in part, unless the Holder
agrees otherwise in writing. This Note may not be changed orally, but only by an

<PAGE>

agreement in writing signed by the party against whom enforcement of any waiver,
change, modification or discharge is sought.

     Maker hereby waives and renounces for itself, its heirs, successors and
assigns, all rights to the benefits of any statute of limitations, any
moratorium, reinstatement, marshaling, forbearance, valuation, stay, extension,
redemption, appraisement and exemption now provided, or which may hereafter by
provided, by the Constitution and laws of the United States of America and of
any state thereof, against the enforcement and collection of the obligations
evidenced by this Note.

     The terms and provisions of this Promissory Note are severable, and if any
term or provision shall be determined to be superseded, illegal, invalid or
otherwise unenforceable in whole or in part pursuant to applicable law by a
court of competent jurisdiction, that determination shall not in any manner
impair or otherwise affect the validity, legality or enforceability of that term
or provision in any other jurisdiction or any of the remaining terms and
provisions of this Note in any jurisdiction.

     No delay or failure on the part of Holder to exercise any power or right
given under this Note shall operate as a waiver of the power or right, and no
course of conduct by Holder shall be deemed to amend or modify this Note or to
affect the meaning or interpretation of any provision hereof. No amendment or
other modification of this Note shall be effective except to the extent
expressly set forth in writing signed by Maker and Holder.

     Any notice required or permitted hereunder shall be in writing and shall be
delivered personally, by overnight courier service or by both registered or
certified mail, return receipt requested, and first class mail, addressed to the
maker at its corporate offices or to the holder at its address set forth above
or at such other more recent address for such party as notice has been given,
and any notice so given shall be deemed received when so personally delivered,
one business day after being so sent by overnight courier service or three (3)
business days after being so mailed.

<PAGE>

     This Note shall be governed by, and interpreted and enforced in accordance
with, the internal laws of the State of New York applicable to contracts
executed, and to be wholly performed, within the State of New York. Any action
brought by either party against the other concerning this Note shall be brought
only in the state courts of New York or in the federal courts located in the
State of New York.

                                             Long Distance Direct Holdings, Inc.

                                             By:  /s/ Steven Lampert

                                                  -------------------
                                                      Steven Lampert
                                                        President

SCHEDULE OF ADVANCES

Date                         Amount

6/12/2000                  $100,000.00
6/19/2000                  $150,000.00
10/03/2000                   $3,000.00
10/24/2000                   $3,000.00
12/02/2000                  $21,000.00
12/21/2000                 $  1,026.60
                           -----------

      Total:               $278,026.60
                           ===========<PAGE>

                                                                    Exhibit 10.5
                                                     August 7, 2000

                            Patent License Agreement

                              Auto-Disable Syringes
<PAGE>

                                    Content

Clause number                                                             Page

1.       Definitions                                                         5
2.       Object                                                              5
3.       Territory                                                           5
4.       The licensors obligations                                           6
4.1.     Transfer of knowledge                                               6
4.2      Patent indemnification                                              7
4.3.     Non-exclusivity                                                     7
4.4.     Payment of duties - maintaining validity of the patent              7
5.       The licensee's obligations                                          7
5.1.     Licence duties                                                      8
5.2      Purchase of equipment                                               8
5.3.     Accounting                                                          8
5A.      Indemnification of the licensed product                             9
5.5.     Regulatory approvals                                                9
5.6      Duty of confidentiality                                             9
6.       Licensee's Warranties                                               9
7        Licensor's Warranties                                              10
8.       Indemnification provisions                                         10
9.       Relationship between parties                                       11
10.      Common stipulations                                                11
10-1.    Property                                                           11
10.2.    Price                                                              11
10.3.    Registration                                                       11
10.4.    Term - cancellation                                                11
10.5     Improvement                                                        12
10.6     Intellectual property                                              12
10.7     Media                                                              12
10.8     Independence of the clauses                                        13
10.9     Notification                                                       13
10.10    Former documents                                                   13
10.11.   Modifications                                                      14
10.12.   Settlement of disputes                                             14
10.13.   Entry into force                                                   14
10.14.   Expenses                                                           14

<PAGE>

PATENT LICENCE AGREEMENT

Auto-Disable Syringes.

         BETWEEN THE UNDERSIGNED:

         Univec Inc. a company having its principal place of business in USA, at
         22 Dubon Court Farmingdale, NY 11735 hereinafter referred to as the
         "licensor",

         and

         Terumo Europe N.V. a company having its principal place of business in
         Belgium at Researchpark 2 Haasrode, Interleuvenlaan 40, B-3001 Leuven
         hereinafter referred to as the "licensee";

HAVING SET OUT THE FOLLOWING:

1. The licensor has made an invention (hereinafter referred to as "the patented
invention", for which he has obtained Patents (hereinafter referred to as "the
Patents").

The Patents and patent applications are listed in Schedule 1 to the present
Agreement.

The licensor wishes to grant a non-exclusive patent licence to the Iicensee, so
that the latter is in a position to manufacture, use and market auto disable
syringes in all types which are covered by any claim of the Patents (hereinafter
referred to as "the Licensed Product"), within the territory specified below.

2. The licensee wishes to obtain the right to manufacture, use and market the
licensed product.

IT HAS BEEN AGREED AS FOLLOWS:

<PAGE>

1.       Definitions

The terms referred to in the Agreement shall have the following meanings:

1. 1     Patents : Patent mean the Patents as well as the patent applications
referred to in Schedule I to this Agreement ;

1.2      Know-How:  Know-How means the body of technical information (including
manufacturing processes, technical experience and drawings) that is relevant for
the manufacturer of the Licensed Product and that has or will be acquired by the
Licensor ;

1.3      Licensed Technology:  Licensed Technology means the technology in the
form of Patents and Know-How or a combination thereof being the object of this
License Agreement when it was concluded and subsequent inclusions or
improvements thereto;

1.4      Licensed Product:  Licensed Product is the product described in
Schedule 2 the manufacturing of which requires the use of the Licensed
Technology.

Capitalized terms used in this Agreement but not defined in this Section I shall
have the meaning given to those terms in the Manufacturing Agreement executed by
the parties (on the same date hereof).

2.       Object

2.1      The Licensor grants the licensee a non-transferable (except as
expressly provided herein) license in order to manufacture, use and market the
Licensed Product.

2.2      The Licensee is entitled during the term of this Agreement to appoint
sub-contractors provided that the sub-contracting will relate only to
well-defined parts of the manufacturing process. The sub-contracting can,
however, cover the entire manufacturing process if the subcontractor is a
company fully owned by the Licensee or its parent company.

The sub-contractor shall be entitled to use the License Technology for the part
of the manufacturing process for which it has been appointed, in the same manner
and under the same conditions which apply to the Licensee under this Agreement

The Licensee is responsible towards the Licensor for the sub-contractors
compliance with all the provision of this License Agreement

3.       Territory

3.1      The parties hereto explicitly agree that the licence shall be granted
worldwide without any restrictions on territories or types of customers
(hereinafter referred to as "the licensed territory'").

3.2      If the licensee requests so in a registered letter the licensor shall,
within a maximum of 90 days as from the receipt of the request referred to and
at his own expense, apply for a patent on existing technology covered by the
Patents for all the countries indicated by the licensee, unless, within that
same period, the licensor notifies the licensee in writing of any reasons
justifying a refusal in which case the obligation will not apply.

3.3      The parties hereto agree that the royalty stipulated in Section 5.1
hereafter will be adjusted or entirely waived with regard to the sale of the
Licensed Product in those markets where Licensor has failed to obtain patent
registration or where as a result Licensee would have to pay additional
royalties to other parties or would have to compete with counterfeit products
infringing the Patents.

<PAGE>

4.       The Licensor's Obligations

4.1      Transfer of knowledge

a.       Within a period of 4 weeks following the signing of this Agreement the
Licensor shall transfer to the Licensee all necessary Licensed Technology to
reasonably enable the latter to exercise its rights under this Agreement .
Licensor shall furthermore promptly transfer to Licensee all Licensed
Technology, which in the future will become known to or will be developed by
Licensor in relation to the manufacturing of the Licensed Product.

b.       The Licensor undertakes to provide the Licensee, within a period of 4
weeks following the signing of this Agreement with all drawings, technology and
intellectual knowledge of Licensor that Licensor has the right to disclose
concerning the manufacture, use and marketing of the Licensed Product If the
permission of a third party would be required to disclose such information,
Licensor would request permission from such party or bring Licensee in contact
with such party in order to obtain permission.

With regard to product volumes other than the 1cc, Licensor shall provide the
Licensee with drawings and technical information only to the extent that:
Supplier has developed or during the term of this Agreement will develop such
drawings and technical information.

c.       In the case of errors, discrepancies and other faults in the drawings
and technical information supplied to the Licensee, the Licensor shall provide
new and correct drawings or information as soon as possible without any cost to
the Licensee.

The Licensor shall compensate the Licensee for any direct costs Incurred as a
result of such errors, discrepancies or faults.

The Licensor shall pay liquidated damages for each week of delay, in providing
the drawings and technical information he is obliged to provide. Notwithstanding
the possibility to prove higher damages,

d.       The Licensor guarantees the Licensee that all patents issued to, owned
or controlled by Licensor and covering the licensed product are given under the
license of the Licensee.

4.2      Patent Indemnification

The Licensor declares that according to his knowledge at the date of signature
of this Agreement, the Licensed Technology does not infringe industrial property
rights of third parties in the territory defined in Section 2.

a.       Licensor agrees, at its own expense, to defend, indemnify and hold
Licensee harmless against any suit claim, or proceeding brought against Licensee
by any third party alleging that manufacture, marketing or use of Licensed
Products infringes any third party patent issued after the effective date of
this agreement or infringement of copyright or trademark or misappropriation of
any trade secret of any third party. As express conditions of Licensors
obligations under this Section Licensee shall (a) immediately notify Licensor in
writing of any such suit claim or proceeding and tender a request for
indemnification hereunder, (b) allow Licensor to assume sole control of the
investigation, defense and settlement of such suit claim or proceeding, (c) give
Licensor information and assistance reasonably necessary for the investigation,
defense aid settlement of such suit, claim, or proceeding, at Licensor's
expense, and (d) not enter into any settlement of any such suit, claim or
proceeding without Licensor's written consent The foregoing indemnity obligation
shall not apply with respect to any product of Licensee or portions or
components thereof that are not covered by at least one claim of the Patent or
part of the Licensed Technology, combined with other products, processes or
materials other than as provided under this Agreement or where Licensee
continues allegedly infringing activity after being notified thereof or after
being informed of modifications that would have avoided the alleged

<PAGE>

infringement; provided that such modifications will be implemented at the
expense of Licensor.

b.       At all times Licensor shall have the right at its sole discretion and
expense to either (i) require Licensee modify the Licensed Product so that it is
not infringing; (ii) obtain for Licensee at Licensor's expense the right to
continue the use of the Licensed Product as licensed hereunder.

c.       The indemnity in this section states the entire liability of Licensor
for infringement of Intellectual Property right by Licensor Products and is in
lieu of any warranty of non infringement of Patent Title and the like, but is
without prejudice to the supplier's warranties under section 7 (e), (f), and
(g).

4.3      Non-exclusivity

The licensor grants a non-exclusive license to the licensee.

4.4      Payment of duties - maintaining validity of the patent

The licensor undertakes to pay all duties regarding the Patents at maturity and
to take all necessary measures with a view to maintaining the validity of the
Patents.

If the licensee requests so the licensor shall submit the proof of payment to
him within 30 days.

The licensor shall allow the licensee the advantage of any more favorable
clauses he may grant third parties on the occasion of patent licence agreements
concerning the patent.

5.       The licensee's obligations

5.1.     Licence duties

The licensee shall owe the licensor a licence duty of:

[OMITTED CONFIDENTIAL INFORMATION] Products sold by the licensee to third
parties and/or sold by sublicensees, if any, for up to [OMITTED CONFIDENTIAL
INFORMATION] pieces of Products per that year

[OMITTED CONFIDENTIAL INFORMATION] sold by the licensee to third parties, and/or
sold by sublicensees, If any, for [OMITTED CONFIDENTIAL INFORMATION] pieces of
Products per that year

[OMITTED CONFIDENTIAL INFORMATION] Products sold by the licensee to third
parties and/or sold by sublicensees, if any, for [OMITTED CONFIDENTIAL
INFORMATION] pieces of Products per that year

No licence duty has to be paid for Products manufactured by the licensee and
sold to the licensor.

No licence duties shall be due with respect to any jurisdiction as from the
moment the invention can be considered to have become public property in such
jurisdiction.

The license duties shall be payable quarterly, in the United States and in
Licensee shall deliver with each quarterly license duty payment a report stating
the number of licensed products sold and the amount of license duty due. License
duties shall accrue upon the earlier of shipment invoicing, or recognition of
revenue by licensee I& licensed products.

No license duties shall be due with respect to any Patent on or after the
effective date of any final judgment of any court of competent jurisdiction,
beyond all right of further appeal by licensor, holding such Patent invalid or
unforceable.

In the event that such a judgment relates only to fewer than all the patents of
which the Patent is comprised, then the licence duty shall be reduced only in
proportion to the remaining number of

<PAGE>

patents that thereafter comprise the Patent. Licensee may not withhold payment
of licence duties or escrow licence duties during the pendency of any
administrative or adversarial proceeding before any agency, court or tribunal in
any jurisdiction pertaining to the licensed Patent or any patent that comprises
the licensed Patent provided, however, that a refund will be made of those
royalties which Licensee will have paid to Licensor during the period between a
judgment rendered by the Court in first instance holding the Patent Invalid or
unenforceable and the final judgment in case of further appeal by Licensor if
the appeal decision declares the Patent to be invalid or unenforceable.

5.2      Purchase of equipment

Except for the Equipment which is covered by the terms of the Equipment Purchase
Agreement, [OMITTED CONFIDENTIAL INFORMATION]

5.3.     Accounting

The licensee undertakes to keep accounts in such a way as to enable to determine
the amount of licensed products he has sold to third parties.

The licensor's auditors alone shall at least once a year be allowed to inspect
the accounts in relation to the business as set out in this Agreement during
normal working hours.

The licensor shall inform the licensee of the intended auditors, visit at least
2 weeks in advance.

Licensee shall have the right to approve the designation of the Licensors audit
firm for the purpose of this Section 4.2, provided that Licensee's approval will
not be unreasonably withheld.

The auditors shall operate at the expense of Licensor except that Licensee shall
reimburse to Licensor the audit fees relating to any particular audit which
would have shown a shortfall in the amount of royalties payable to Licensor of
more than 10%. This penalty shall not apply in case the shortfall is due only to
a technical delay in the processing of the accounting data or attributable to
causes beyond the control of Licensee (such as technical error or failure of
accounting software).

5.4      Identification of the licensed product

In order to distinguish the licensed product the licensee shall use his own
brand name, package and lot number, and assign a TERUMO-product code, separate
from the product code produced under the brand name (label) of UNIVEC in
application of the Manufacturing agreement The licensee shall indicate himself
as the manufacturer.

5.5      Regulatory approvals

The licensee shall have the responsibility for obtaining export licenses and
clearances and all other regulatory approvals for the marketing and sale of the
Licensed Products.

5.6      Duty of confidentiality

Each Party undertakes to keep the Confidential Information which it has acquired
from the other party within the framework of the present agreement secret both
during and after the execution of the present agreement.

<PAGE>

When subcontracting is authorized in accordance with the provisions of Section 2
above, the Licensee guarantees that he will impose the same level of
confidentiality on those subcontractors.

6.       Licensee's Warranties

The Licensee represents and warrants to the Licensor that:

(a)      it is a corporation duly formed and validly existing under the laws of
Belgium.

(b)      it does not lack the necessary corporate power and authority to enter
into this Agreement and perform obligations under it and its execution, delivery
and performance of this Agreement have been duly authorized by all necessary
corporate actions;

(c)      neither the execution and delivery of this Agreement nor the
performance by it of this Agreement will violate any provision of its
Certificate of Incorporation and by-laws;

(d)      the Licensee has not taken any action which would preclude or adversely
affect the Licensee's full performance of this Agreement nor failed to take any
action necessary in order to authorize or enable such performance;

(e)      it has the capacity, ability and all property, including intellectual
property, necessary to perform its obligations under the Agreement

7.       Licensor's Warranties

The Licensor represents and warrants to the Licensee that

(a)      Licensor is a corporation duly formed and validly existing under the
laws of the state of Delaware, USA;

(b)      Licensor has the necessary corporate power and authority to enter into
and perform obligations under this Agreement and the Clients execution, delivery
and performance of this Agreement has been duly authorized by all necessary
corporate action;

(c)      neither the execution and delivery of this Agreement nor the
performance by the Licensor of this Agreement will violate any provision of the
Licensor's Certificate of incorporation and by-laws;

(d)      Licensor has neither taken any action which would Preclude or adversely
affect the Licensors full performance of this Agreement nor failed to take any
action necessary in order to authorize or enable such performance;

(e)      Licensors Intellectual Property Rights and other rights in and to the
Products do not at the date of this Agreement prevent it from granting the
rights to the Licensee under this Agreement and will not affect those rights
during the Term;

(f)      subject to Section 4.2 above, nothing in this Agreement win infringe
any intellectual property and other rights of any third party including but not
limited to any rights which a third party may have to or in the Products: and

(g)      Licensor has the capacity, ability and all property, including
intellectual property, necessary to perform its obligations under the Agreement

<PAGE>

8.       Indemnification provisions

Unless otherwise stated In the present Agreement, the following indemnification
shall apply:

1.       Neither party shall be liable to the other party for any loss or damage
whatsoever or howsoever arising directly or indirectly in connection with this
Licensing Agreement the Licensed Technology, its use or otherwise except as
provided in this Agreement.

2.       In no event shag either party be liable towards the other party (or
indemnify such other party) for any indirect or consequential loss or damage,
howsoever arising, or any loss of revenues, profits or goodwill.

3.       Each party shall be liable (and indemnify the other party) for the
death, personal injury and direct costs resulting from the negligence of such
party or the negligence of such party's employees, agents or contractors.

4.       The provisions of this clause shall remain in force notwithstanding
termination of this Agreement.

9.       Relationship between parties

Neither party shall represent or hold itself out to any third party as being a
representative or agent of each other except as authorized by this Agreement or
otherwise in writing by the other party;

Neither party shall conclude or purport to conclude any contract or agreement or
make or purport to make any commitment representation, misrepresentation or
warranty on behalf of or which binds the other party or otherwise act in to name
of or on behalf of the other party without the prior written consent of the
other,

The Licensor and Licensee acknowledge and agree that:

(a)      nothing in this Agreement shall be construed as creating the
relationship of principal and agent or a partnership between Licensor and
Licensee; and

(b)      this Agreement is personal to each of the Licensor and Licensee and
shag not be assigned by or without the prior written consent of the other party
except as otherwise authorized by this Agreement.

10.      Common stipulations

10.1.    Property

The parties agree explicitly that the Licensor is and shall remain the owner of
the Patents (until the expiration date of each Patent) and of the Know-How,
relating to the Licensed Product.

10.2.    Price

[OMITTED CONFIDENTIAL INFORMATION]

10.3.    Registration

If necessary the parties shall take all necessary measures with a view to having
the present patent licence agreement registered with the competent national or
international administrations. The costs such registration involves shall be
defrayed by the licensor.

<PAGE>

10.4.    Term - cancellation

1.       The Agreement shall remain in force for the entire validity of the
Patents, with the option for the Licensee to terminate the License Agreement
after 5 years as from the date of the last signature of this Licensing Agreement
with a notice period of 3 months prior to the termination date. If the Agreement
is not terminated by Licensee, it will automatically be renewed for consecutive
periods of 5 years each with the option for Licensee to terminate the Licensing
Agreement towards the end of each such period, with a notice of 3 months prior
to the termination date.

2.       If one or more additional patents issue to the Licensor during the term
of the Agreement, and any such additional patent contains at least one claim
that reads on a Licensed Product or any component thereof, then such additional
patent shall automatically become part of the Patents hereunder.

3.       The licensee shall be entitled to terminate the present agreement
forthwith by means of a registered letter if the use of the rights ensuing from
the present agreement should prove to constitute an infringement on the rights
of any third party.

4.       Immediate termination

a.       This agreement may be terminated with immediate effect and without
prior recourse to the courts upon the provision of written notice to the other
party when either of the parties fails to perform or fails to observe any of its
essential obligations under this Agreement and if such default (if it is
curable) is not cured within 30 days after the default has been notified to the
defaulting party. For the purpose of this sub-clause (a) the following
obligations are (as an example and without limitation) considered to be
essential: the obligations of the Licensor stipulated in Section 3 and Section
4;

b.       when Licensee challenges the validity of any Patent.

5.       The Licensor's obligations stipulated in Sections 4.1, 4.2 and 7 (f)
shall survive the termination of this Agreement.

10.5     Improvement

All rights with regard to patentable improvements in either the Licensed
Technology shall be jointly held by Licensor and Licensee.

Either party shall be entitled to use the improved technology for its own
production (whether by third parties or otherwise) without the permission of or
the payment of a royalty to the other party. Either party shall have the right
to license the developed technology to any third party, except that licenses to
related parties shall need the consent of the other party on the amount and
payment of the royalty.

Any revenues deriving from licensing this developed technologies to third
parties shall be shared equally between the parties.

10.6     Intellectual property

The parties agree that the Patents and Licensed Technology are intellectual
property as that term is used in the US Bankruptcy Code. The parties acknowledge
that the Licensee may invoke and exercise any and all rights at law including
the rights under I I USC Section 365.

The foregoing provision does not otherwise affect the chore of law applicable to
this Agreement

<PAGE>

10.7     Media

Each Party shall refrain from issuing or conducting any interview, report or
press release regarding the existence or terms of this agreement unless the
statement is provided in advance for review by the other party and the comments
of the other party incorporated in the reasonable discretion of the disclosing
party. Further, unless the disclosing party reasonably believes it to be
required by law or rule of any stock exchange on which such party's stock is
listed or quoted, neither party shall issue any press release regarding the
existence or terms of this agreement to which the other party shall reasonably
object.

10.8     Independence of the clauses

If any of the clauses or provisions contained in the present agreement should be
declared null and void this nullity shall not affect the other clauses or
provisions thereof.

10.9     Notification

All notices must be:

(a)      in legible writing and in English;

(b)      addressed to the recipient at the address or facsimile number set out
below or to any other address or facsimile number that a party may notify to the
other party:

         to the Licensee:

         Terumo Europe N.V.
         Researchpark 2 Haasrode, Interleuvenlaan 40, B-3001 Leuven, Belgium.

         to the Licensor:

         Univec Inc
         22 Dubon Court Farmingdale, NY 11735, USA.

(c)      signed by the party or, where the sender is a company, by an authorized
officer or under the common seal of the sender, and

(d)      sent to the recipient by hand, prepaid post airmail or facsimile or
e-mail.

Without limiting any other means by which a party may be able to prove that a
notice has been received by the other party, a notice will be considered to have
been received

(a) if sent by hand, when left at the address of the recipient;

(b) if sent by pre-paid post 10 days after the date of posting; or

(c)      if sent by facsimile, on receipt by the sender of an acknowledgment or
transmission report generated by the sender's machine indicating that the whole
facsimile was sent to the recipients facsimile number,

(d)      E-mails; are only accepted as valid notification after confirmation of
receipt has been sent by the party to whom the e-mil was sent.

but if a notice is served by hand, or is received by the recipient's facsimile,
on a day that is not a Business Day, or after 5:00 p.m. (recipients local time)
on a Business Day, the notice will be considered to have been received by the
recipient at 9.00 am on the next Business Day.

<PAGE>

10.10    Former documents

The present agreement replaces any former oral, written or tacit agreement and
document existing between the parties hereto and relating to the subject matter
of the present Agreement.

This Section 10.8 does not affect the Manufacturing Agreement which the parties
have concurrently executed.

10.11.   Modifications

Any modification to the present agreement shall be made in writing.

10.12.   Settlement of disputes

In the event of any dispute, controversy or difference arising in connection
with this Agreement, the parties shall endeavor to settle the issue in an
amicable manner.

If no amicable solution can be reached, the matter shall be finally settled by
the Rules of Arbitration of the International Chamber of Commerce by one or more
arbitrators appointed in accordance with the said rules under the authority of
the ICC Secretariat in Paris (France).

10.13.   Entry Into force

The present agreement shall come into effect upon signing.

10.14    Expenses

Each party shall bear its own costs in connection with the negotiation and
conclusion of the present Agreement.

Thus executed on 16 Aug. 2000 at Leuven in 2 originals, one for each party and a
copy for the purpose of registration.

Executed as an agreement

Signed for and on behalf of               Signed for and on behalf of
Univec Inc.                               Terumo Europe N.V.
By its duly authorized representative     by its duly authorized representative

Name:    /s/Joel Schoenfeld               Name: /s/ J. Nakajima

Title:   Chairman                         Title: Vice President

Date:    August 11, 2000                  Date: August 16, 2000

<PAGE>

                                   Schedule 1

    Univec Patents and Patent Applications Relevant to Auto-Disable Syringes
                                (April 19, 2000)

<TABLE>
<CAPTION>
      LLBL
No.   File No.        Title                               Patent No.            Country              Status/Comment
-------------------------------------------------------------------------------------------------------------------
<S>   <C>             <C>                                 <C>                   <C>                  <C>
1.    1128.006        Single Use Syringe Assembly         U.S. Patent No.       1. United States     Issued Jul. 2 1996
                                                          5,531,691                                  17 Claims

2.    1128.010        Single-Use Syringe Assembly         U.S. Patent No.       2. United States     Issued Oct 8, 1996
                      Including Spring clip               5,562,623                                  CIP of U.S. Patent
                      Lock and plunger                                                               No.5,531,691;
                                                                                                     27 Claims

3.    1128.010        Single-Use Syringe Assembly         WO 95/21649           3. PCT               PCT application
                      Comprising Spring Clip Lock                                                    Corresponding to
                      and Plunger                                                                    Items 1 and 2.

4.    1128.010.004    Single-Use Syringe Assembly         689862(18428/95)      4. Australia
                      Comprising Spring Clip Lock
                      and Plunger

5.    1128.010.008    Single use Syringe Assembly         PI 95067680           5. Brazil
                      Comprising Spring Clip Lock
                      and Plunger

6.    1128.010.010    Single Use Syringe Assembly         2,183,324             6. Canada
                      Comprising Spring Clip Lock
                      and Plunger

7.    1128.010.015    Single-Use Syringe Assembly         95192421.4            7. China
                      Comprising Spring Clip Lock
                      and Plunger

8.    1128.010.042    Single-Use Syringe Assembly         963374                8. Mexico
                      Comprising Spring Clip Lock
                      and Plunger

9.    1128.010.045    Single-Use Syringe Assembly         96118475              9. Russia
                      Comprising Spring Clip Lock
                      and Plunger

10.   1128.010.074    Single-Use Syringe Assembly         96-704556             10. Korea
                      comprising Spring Clip Lock
                      and Plunger

11.   1128.010.075    Single Use Syringe Assembly         95910244.3            11. EPO
                      Comprising Spring Clip Lock
                      and Plunger

12.   1128.020 PCT    Single Use Syringe With             PCTUS96/06597         12. PCT              The following
                      Aspirating Mechanism                                                           National Phase
                                                                                                     applications were
                                                                                                     pursued from this
                                                                                                     PCT application
</TABLE>

<PAGE>
<TABLE>
<CAPTION>
      LLBL
No.   File No.        Title                               Patent No.            Country              Status/Comment
-------------------------------------------------------------------------------------------------------------------
<S>   <C>             <C>                                 <C>                   <C>                  <C>
13.   1128.020        Single Use Syringe With             09/171,274            13 US
                      Aspirating Mechanism

14.   1128.020.004    Single Use Syringe With             5856298               14. Australia
                      Aspirating Mechanism

15.   1128.020.008    Single Use Syringe With             PI 9612678-7          15.Brazil
                      Aspirating Mechanism

16.   1128.020.010    Single Use Syringe With             2,253,973             16.Canada
                      Aspirating Mechanism

17.   1128.020.015    Single Use Syringe With             96180356.8            17.China
                      Aspirating Mechanism

18.   1128.020.029    Single Use Syringe With             99104484.7            18.Hong Kong
                      Aspirating Mechanism

19.   1128.020.042    Single Use Syringe With             989340                19.Mexico
                      Aspirating Mechanism

20.   1 128.020.04    Single Use Syringe With             98122433              20.Russia
                      Aspirating Mechanism

21.   1128-020-074    Single Use Syringe With             98-709014             21.Korea
                      Aspirating Mechanism

22.   1128.020.075    Single Use Syringe With             96920171.4            EPO
23.                   Aspirating Mechanism

24.   1.1128.016      Insertable Element for              U.S. Patent No.       U.S.                 Univec has
                      Preventing Reuse of Plastic         5,205,825                                  exclusive and
                      Syringes                                                                       non-exclusive
                                                                                                     patent rights from
                                                                                                     the inventors:
                                                                                                     Richard A Jaffe and
                                                                                                     Alan C. Allison.

25.   Z1128.002       1. Restricted Use Hypodermic        1-U.S. Patent No.     U.S.                 Univec has
                      Syringe                             5,021,047                                  acquired license
                                                                                                     from the inventor
                                                                                                     John B. Movern

      3.1128.002      Restricted Use Hypodermic           U.S. Patent No.       U.S.                 Univec has
                      Syringe                             5,183,466                                  acquired Iicense
                                                                                                     from the inventor
                                                                                                     John B. Movern

26.                   Single Use Hypodermic               U.S. 5,370,620        U.S.
                      Syringe
</TABLE>

<PAGE>

                                   Schedule 2

                         Licensed Product - Description.

Univec will be licensing its Auto Disable Syringes "AD-Sy" of various
medical-sized volumes and barrel dimensions.

o        The Licensed Product refers to AD-Sy and has any one or more of the
         following three different mechanisms, all of which accomplish the same
         desired end-result i.e., an automatically disabled syringe such that it
         cannot be used a second time.

o        A first mechanism has a radially resilient locking spring clip attached
         around a ratcheted, basically cylindrical plunger. This is generally
         shown in US Patent Nos. 5,531,691; 5,562,623; and pending US patent
         application 09/171,274. PCTs and National Phases correspond to the US
         patents and applications. A version of this resilient spring clip has
         the clip extend only about 23 degrees around the cylindrical plunger.

o        A second embodiment of an AD-Sy which is to be licensed under the
         Univec technology relates to the use of an X-shaped plunger Here, the
         clip is U-shaped with a channel which clips onto one of the ribs of the
         X-shaped plunger. This is generally shown in US Patent No. 5,205,825 to
         Alison and Jaffe. The Alison/Jaffe embodiment is licensed to Univec on
         an exclusive basis so long as certain minimum payments are made and is
         non-exclusive to Univec if the minimums are not kept The royalties to
         be paid are based on certain conditions which are not pertinent to your
         agreement with Univec.

o        A third embodiment of an AD-SY, also to be licensed by Univec to
         Terumo, is a plunger lock which fully surrounds a cylindrical,
         ratcheted plunger rod. This device is generally shown in the two Movern
         US patents, namely, US patents Nos. 5,021,047 and 5,183,466. These
         patents are exclusively licensed to Univec.

o        The plunger can have an additional piston gasket attached to it that
         provides for the sealing between the plunger rod and the inner syringe
         wall or the sealing can be provided by the contact between an element
         of the plunger rod itself and the inner syringe wall.

o        A single use syringe is provided having:

         a)    a rod-like plunger comprising a plurality of ratchet teeth or by

         b)    an X-shaped (in cross section) plunger in the case of the
         U-shaped clip similar to the Alison-Jaffe embodiment In the
         cylindrical rod like plunger, for both the resilient spring clip
         mechanism and the plunger lock (the barrel of Movern) embodiments, the
         clip or plunger lock is held on the ratchet teeth. For the X-shaped
         rod, the U-shaped clip is held onto one of the ribs of the plunger. In
         all of the embodiments, the original location of the locking mechanism
         with respect to the plunger rod and the barrel of the syringe
         determines the maximum dosage which may be administered by the
         syringe. A first withdrawal of the plunger with respect to the barrel
         allows medication to be drawn into the barrel. In the embodiment of
         the resilient spring clip, the spring dangles on the ratchet teeth of
         the plunger. The tab of the locking spring resiliently cams over the
         surface of the ratchet teeth. In all three embodiments, the locking
         mechanism is maintained in position along the barrel by at least one
         outwardly directed contact point which embeds into the interior side
         wall of the barrel. During administration of the medication, i.e.,
         distal movement of the plunger rod with respect to the barrel, the
         locking spring, the U shaped clip and the plunger locking barrel (of
         the Movern embodiment) cooperate With the ratchet teeth for the
         cylindrical ratcheted version or the surface of the X-shaped plunger
         rod to cause the locking mechanism to move along with plunger
         movement. A second attempted withdrawal of the plunger is blocked once
         the locking mechanism (of all three types) has been moved by the
         plunger rod to its full distal position.

<PAGE>

o        The design with the resilient locking spring, the U-shaped clip and the
         plunger locking barrel (of the Movern embodiment) allow for aspiration
         and with multiple sized syringes which can be used for curative
         purposes by having pre-determined numbers and locations of ratchets.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]